Company intelligence / Profile preview

PanCAD.ai Co., Ltd.

Ownership: Private
Development stage: Commercial

Overview

PANCREASaver is an AI-powered tool for detecting pancreatic cancer with high accuracy, approved by the Taiwan FDA and designated as a Breakthrough Device by the US FDA.

Therapeutic areas: Oncology
Modalities: AI-assisted Diagnostic Tools
Industry: Digital Health Medical Devices

Drug pipeline

1 asset

PANCREASaver

Commercial

Indications: Pancreatic cancer

Partnerships

Taipei City GovernmentNational Taiwan UniversityNational Taiwan University Hospital

Beyond the preview

Go deeper on PanCAD.ai Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PanCAD.ai Co., Ltd..

Explore the full profile